Immunocore Holdings (IMCR) Non-Current Deffered Revenue (2019 - 2026)

Immunocore Holdings has disclosed Non-Current Deffered Revenue across 8 years of filings, most recently posting $4.6 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $4.6 million, down 17.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (down 17.64% YoY), and the FY2025 annual result was $4.9 million, down 10.6% from the prior year.
• Non-Current Deffered Revenue came in at $4.6 million for Q1 2026 at Immunocore Holdings, down from $4.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $5.8 million in Q3 2024 to a low of $4.6 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $5.4 million (2024), against an average of $5.3 million.
• Across the five-year window, Non-Current Deffered Revenue plunged 41.19% in 2022 and rose 8.56% in 2023, its largest moves.
• Immunocore Holdings' Non-Current Deffered Revenue stood at $5.1 million in 2022, then increased by 8.56% to $5.5 million in 2023, then fell by 1.47% to $5.4 million in 2024, then fell by 10.6% to $4.9 million in 2025, then slipped by 4.86% to $4.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $4.6 million (Q1 2026), $4.9 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.